Nanda Anil, Konar Subhas K, Maiti Tanmoy K, Bir Shyamal C, Guthikonda Bharat
Department of Neurosurgery, LSU Health-Shreveport, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.
Department of Neurosurgery, LSU Health-Shreveport, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.
Clin Neurol Neurosurg. 2016 Mar;142:31-37. doi: 10.1016/j.clineuro.2016.01.005. Epub 2016 Jan 11.
OBJECTIVE: Meningiomas of the clinoidal region pose significant surgical challenges due to their close proximity and intimate relation with surrounding critical neurovascular structures. Our aim was to describe our institution's experience with the management of clinoidal meningiomas, identify predictive factors and develop a comprehensive grading system to assess the extent of resection. METHODS: The medical records of 36 consecutive patients underwent surgery from 1995 to 2015 with clinoidal meningiomas were retrospectively reviewed. Using selected clinical features and tumor characteristics, a grading scale was devised and utilized to assess a degree of tumor resectability. The factors included: preoperative visual status(no visual loss=0, visual loss=1), tumor volume: small (<13.5 cm(3)=1), moderate (13.5-30 cm(3)=2), and large (>30 cm(3)=3),relationship with the internal carotid artery (no displacement=0, displacement=1, encasement=2, stenosis=3 and bilateral involvement=4) tumor extension into the cavernous sinus (yes=1, no=0) and invasion into the optic canal (yes=1, no=0), (defined as tumor beyond the falciform ligament). A grading system was designed using the total scores (10) in this classification and separating patients into two groups: group 1 with scores of 5 or less, group 2 with scores more than 5. RESULTS: The patients mean age at the time of intervention was 61 years. The tumor involved the cavernous sinus in 38.9% of patients and invaded the optic canal in 36% of cases. The patient presented with visual impairment in 89% of cases. Vision improved in 28% and remained stable in 63% of cases. The mean volume of a tumor was 16.99 cm(3). The most common approach involved pterional with or without anterior clinoidectomy. After stratification, group 1 consisting of 22 patients and in group 2, 14 patients. Gross total resection (Simpson Grade I or II) was achieved in 75% of surgeries and subtotal and partial resections were achieved in 25% of cases. Group 1 patients had higher gross total resection rate than group 2 (p=0.009). Only optic canal involvement was significantly associated with the extent of resectabilty in a univariate analysis (p=0.03). Four patients developed tumor recurrence with median recurrence duration of 89 months (53-204 months). Three patients underwent GKRS and one patient underwent repeat surgery at the time of recurrence. CONCLUSIONS: A grading system can be employed in patients who present with clinoidal meningiomas and serve as an aid in planning an appropriate treatment strategy and establishing the prognosis. Radical resection can be planned in patients with favorable tumor criteria (groups 1) while a less aggressive surgical approach followed by stereotactic radiosurgery may be better suited for patients with less favorable tumor characteristics (group 2).
目的:鞍旁区脑膜瘤因其与周围重要神经血管结构距离近且关系密切,给手术带来了重大挑战。我们的目的是描述我们机构处理鞍旁脑膜瘤的经验,确定预测因素,并制定一个全面的分级系统来评估切除范围。 方法:回顾性分析1995年至2015年连续36例接受鞍旁脑膜瘤手术患者的病历。利用选定的临床特征和肿瘤特征,设计并使用一个分级量表来评估肿瘤的可切除程度。因素包括:术前视力状况(无视力丧失=0,视力丧失=1)、肿瘤体积:小(<13.5 cm³=1)、中(13.5 - 30 cm³=2)、大(>30 cm³=3)、与颈内动脉的关系(无移位=0,移位=1,包绕=2,狭窄=3,双侧受累=4)、肿瘤向海绵窦扩展(是=1,否=0)以及侵犯视神经管(是=1,否=0)(定义为肿瘤超出镰状韧带)。使用该分类中的总分(10分)设计一个分级系统,并将患者分为两组:第1组得分5分或以下,第2组得分超过5分。 结果:干预时患者的平均年龄为61岁。38.9%的患者肿瘤累及海绵窦,36%的病例侵犯视神经管。89%的病例患者存在视力损害。28%的病例视力改善,63%的病例视力保持稳定。肿瘤的平均体积为16.99 cm³。最常见的手术入路包括翼点入路,可联合或不联合前床突切除术。分层后,第1组有22例患者,第2组有14例患者。75%的手术实现了全切除(辛普森I级或II级),25%的病例实现了次全切除和部分切除。第1组患者的全切除率高于第2组(p=0.009)。单因素分析中,仅视神经管受累与可切除程度显著相关(p=0.03)。4例患者出现肿瘤复发,复发持续时间中位数为89个月(53 - 204个月)。3例患者接受了伽玛刀放射外科治疗,1例患者在复发时接受了再次手术。 结论:分级系统可用于鞍旁脑膜瘤患者,有助于制定合适的治疗策略和判断预后。对于肿瘤标准良好的患者(第1组)可计划进行根治性切除,而对于肿瘤特征较差的患者(第2组),采用较保守的手术方法后再行立体定向放射外科治疗可能更合适。
Clin Neurol Neurosurg. 2016-3
J Neurosurg. 2012-8-17
Neurosurg Focus. 2018-4
Acta Neurochir (Wien). 2008-11
Acta Neurochir (Wien). 2012-9-4
World Neurosurg. 2021-2
Acta Neurochir (Wien). 2013-5-11
Cureus. 2023-6-8
J Neurol Surg B Skull Base. 2022-11-12
Acta Neurochir (Wien). 2021-12